Amarin sues looming Vascepa competitor

|About: Amarin Corporation PLC (AMRN)|By:, SA News Editor

Amarin (AMRN) sues Omthera Pharmaceuticals, now part of AstraZeneca (AZN), claiming its cholesterol-lowering drug, Epanova, infringes on one of Vascepa's patents.

Epanova's target user population is the same as Vascepa's and GSK's Lovaza.

AZN expects the FDA to rule on Epanova's NDA by May 5.

Lovaza sales are ~$1B.